Oligodendrogliomas: a short history of clinical developments.
作者信息
van den Bent Martin J
机构信息
Brain Tumor Center at Erasmus MC Cancer Center, Erasmus MC, Rotterdam, The Netherlands.
出版信息
CNS Oncol. 2015;4(5):281-5. doi: 10.2217/cns.15.35.
Abstract
摘要
相似文献
1
Oligodendrogliomas: a short history of clinical developments.
CNS Oncol. 2015;4(5):281-5. doi: 10.2217/cns.15.35.
2
Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.
Acta Neurochir (Wien). 2020 Dec;162(12):3019-3024. doi: 10.1007/s00701-020-04514-3. Epub 2020 Aug 12.
3
Oligodendrogliomas: molecular biology and treatment.
Oncologist. 2009 Feb;14(2):155-63. doi: 10.1634/theoncologist.2008-0248. Epub 2009 Jan 31.
4
Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.
Oncology (Williston Park). 2013 Apr;27(4):315-20, 322.
5
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.
Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26708. Epub 2017 Jul 11.
6
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
J Clin Oncol. 2006 Oct 10;24(29):4746-53. doi: 10.1200/JCO.2006.06.3891. Epub 2006 Sep 5.
7
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Eur J Cancer. 2006 Oct;42(15):2499-503. doi: 10.1016/j.ejca.2006.05.021. Epub 2006 Aug 17.
8
Low-grade and anaplastic oligodendroglioma.
Handb Clin Neurol. 2016;134:361-80. doi: 10.1016/B978-0-12-802997-8.00022-0.
9
Grade II and III Oligodendroglioma and Astrocytoma.
Neurol Clin. 2018 Aug;36(3):467-484. doi: 10.1016/j.ncl.2018.04.005. Epub 2018 Jun 15.
10
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
J Clin Oncol. 2006 Jun 20;24(18):2707-14. doi: 10.1200/JCO.2005.04.3414.
引用本文的文献
1
Q-Ball high-resolution fiber tractography: Optimizing corticospinal tract delineation near gliomas and its role in the prediction of postoperative motor deficits- A proof of concept study.
Brain Spine. 2024 Nov 14;4:104139. doi: 10.1016/j.bas.2024.104139. eCollection 2024.
2
A Rare Presentation of Multifocal Anaplastic Oligodendroglioma.
J Microsc Ultrastruct. 2022 Aug 4;11(2):115-117. doi: 10.4103/jmau.jmau_126_20. eCollection 2023 Apr-Jun.
3
Role of Temozolomide Regimen on Survival Outcomes in Molecularly Stratified WHO Grade II Gliomas: A Systematic Review.
Asian J Neurosurg. 2021 Feb 23;16(1):14-23. doi: 10.4103/ajns.AJNS_186_20. eCollection 2021 Jan-Mar.
本文引用的文献
1
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6. doi: 10.1073/pnas.1303607110. Epub 2013 Mar 25.
2
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
J Clin Oncol. 2013 Jan 20;31(3):337-43. doi: 10.1200/JCO.2012.43.2674. Epub 2012 Oct 15.
3
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
J Clin Oncol. 2013 Jan 20;31(3):344-50. doi: 10.1200/JCO.2012.43.2229. Epub 2012 Oct 15.
4
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
Oncotarget. 2012 Jul;3(7):709-22. doi: 10.18632/oncotarget.588.
5
Mutations in CIC and FUBP1 contribute to human oligodendroglioma.
Science. 2011 Sep 9;333(6048):1453-5. doi: 10.1126/science.1210557. Epub 2011 Aug 4.
6
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
J Clin Oncol. 2009 Dec 10;27(35):5874-80. doi: 10.1200/JCO.2009.23.6497. Epub 2009 Nov 9.
7
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
J Clin Oncol. 2009 Dec 10;27(35):5881-6. doi: 10.1200/JCO.2009.24.1034. Epub 2009 Nov 9.
8
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
Neuro Oncol. 2009 Dec;11(6):737-46. doi: 10.1215/15228517-2009-011.
9
Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.
Brain Pathol. 2008 Jul;18(3):360-9. doi: 10.1111/j.1750-3639.2008.00129.x. Epub 2008 Mar 26.
10
The 2007 WHO classification of tumours of the central nervous system.
Acta Neuropathol. 2007 Aug;114(2):97-109. doi: 10.1007/s00401-007-0243-4. Epub 2007 Jul 6.
Zotero 插件